An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
NCT ID: NCT05757141
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
50 participants
INTERVENTIONAL
2023-03-13
2029-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fosigotifator - Cohort 1
Cohort 1: VWM adults \>= 18 years.
Fosigotifator
Oral Use
Fosigotifator - Cohort 1b
Cohort 1b: VWM adults \>= 18 years.
Fosigotifator
Oral Use
Fosigotifator - Cohort 2
Cohort 2: VWM children\>= 12 y and \<18 years.
Fosigotifator
Oral Use
Fosigotifator - Cohort 3
Cohort 3: VWM children \>= 6 y and \<12 years.
Fosigotifator
Oral Use
Fosigotifator - Cohort 4
Cohort 4: VWM children \>= 6 months and \<6 years.
Fosigotifator
Oral Use
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fosigotifator
Oral Use
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have VWM disease defined as:
1. A clinical diagnosis by a physician experienced in the assessment of VWM disease; and
2. A molecular diagnosis of VWM disease, and
3. A magnetic resonance imaging (MRI) presentation consistent with VWM disease.
3. Have a designated caregiver who is able to complete the respective caregiver-centered assessments.
4. Signed and dated informed consent provided by the participant, or from a legally authorized representative (LAR) if participant is incapable to consent themselves.
5. Participants must meet criteria (a) and at least one of the following functional criteria (b or c):
1. Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease.
2. Motor criteria defined as inability to walk 10 or more steps with or without light support of 2 hands
3. Cognitive criteria as assessed by the age-appropriate version of the Wechsler Intelligence Scale, with participants scoring \< 50 on specific indices; specific details can be provided by the Study physician.
6. Pediatric participants in Cohort 4 must meet both criteria a and b below, or criterion c:
1. Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease.
2. Motor criteria as defined below:
i. More than minimal head control as demonstrated by: While in prone position, the participant can lift his/her head and sustain the position for 10 seconds and bring his/her arms actively to weight bearing in that position.
c. Presymptomatic and homozygous for Cree Leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (sponsor must be notified and provide approval prior to screening and enrolling a participant that meets eligibility with only this criterion).
7. All male participants who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male participants must agree to not donate sperm during the study until 30 days after the final dose of study drug.
8. All female participants who are sexually active and of childbearing potential must agree to use a highly effective contraceptive method. Additionally, female participants must agree to not donate eggs during the study and for 30 days after the final dose of study drug.
Exclusion Criteria
2. Changes in medication use for the management of VWM disease symptoms within the 4 weeks preceding Screening.
3. Seizure disorder not considered adequately controlled by the investigator within the 6 months preceding Screening.
4. Participant who, in the opinion of the investigator, is incapable of completing study-required visits and procedures to assess primary and secondary endpoints.
5. Adult female participants who are pregnant, breastfeeding or providing breast milk.
6. Treatment with any other investigational treatment within 30 days or 5 half-lives (whichever is longer) prior to Baseline.
7. Any clinically significant laboratory or imaging findings at Screening.
6 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Calico Life Sciences LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital /ID# 270960
Boston, Massachusetts, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
University of Utah /ID# 255624
Salt Lake City, Utah, United States
McGill University Health Centre - Glen Site
Montreal, Quebec, Canada
Amsterdam UMC, locatie VUmc /ID# 270955
Amsterdam, North Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-505704-30-00
Identifier Type: OTHER
Identifier Source: secondary_id
M23-523
Identifier Type: -
Identifier Source: org_study_id